The UK and US have reached a major trade agreement that will guarantee no levies on British drug products being sold in the US market.
The Terms of the Pact
Under the terms of the agreement, the UK has agreed to increase expenditure on pharmaceuticals through the NHS. This move ensures that import taxes on these crucial products will be held at zero for a timeframe of 36 months.
This agreement comes after earlier warnings to dramatically increase tariffs on branded drug products, with potential rates floated up to 100%.
"This agreement with the United Kingdom reinforces the international landscape for innovative medicines and brings long-overdue equity to U.S.–U.K. drug exports," an announcement declared.
Commercial Significance
Drugs constitute one of the Britain's biggest goods shipped to the US, which is easily the primary destination for leading British pharmaceutical firms.
Trade data show that in the 12 months to the end of September, the UK sold medicines totaling over eleven billion pounds to the US. This value represented a significant portion of total UK exports in that period.
"This agreement secures employment, stimulates investment and sets the stage for the UK to emerge as a global hub for medical research," the Business and Trade Secretary commented.
Detailed UK Commitments
The agreement involves several specific commitments from the UK:
- Higher Cost Ceiling: The UK will increase the price threshold at which it considers new treatments to be unaffordable by twenty-five percent.
- Increased NHS Spending: There is a target to raise total public funding on drugs from 0.3 percent of Gross Domestic Product to 0.6 percent over the next decade.
- Refund Ceiling: The percentage pharmaceutical firms must refund to the NHS to control costs will be restricted at 15%. In the past, repayments exceeded twenty percent.
Recent Tensions
The deal takes place against a protracted tension between the drug companies and the UK government over drug pricing and approval rates.
These tensions were intensified by claims that American patients were paying several times more for the equivalent treatments than patients in the other developed nations.
Recently, several large drug company projects in the UK have been halted or cancelled, while multi-billion-dollar expansions have been pledged toward US facilities.
One official acknowledged that the NHS must invest a greater share on drugs, noting that its expenditure on drugs had declined as a share of its total funding over the past decade.
